粘上
发表于 2025-3-21 17:39:05
书目名称New Therapeutic Strategies in Lung Cancers影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0665852<br><br> <br><br>书目名称New Therapeutic Strategies in Lung Cancers影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0665852<br><br> <br><br>书目名称New Therapeutic Strategies in Lung Cancers网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0665852<br><br> <br><br>书目名称New Therapeutic Strategies in Lung Cancers网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0665852<br><br> <br><br>书目名称New Therapeutic Strategies in Lung Cancers被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0665852<br><br> <br><br>书目名称New Therapeutic Strategies in Lung Cancers被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0665852<br><br> <br><br>书目名称New Therapeutic Strategies in Lung Cancers年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0665852<br><br> <br><br>书目名称New Therapeutic Strategies in Lung Cancers年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0665852<br><br> <br><br>书目名称New Therapeutic Strategies in Lung Cancers读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0665852<br><br> <br><br>书目名称New Therapeutic Strategies in Lung Cancers读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0665852<br><br> <br><br>
fibula
发表于 2025-3-21 21:14:30
http://reply.papertrans.cn/67/6659/665852/665852_2.png
1分开
发表于 2025-3-22 02:47:11
Book 2015re also highlighted..Written by recognized experts in their field, the book represents a unique and valuable resource in the field of lung cancer, both for those currently in training and for those already in clinical or research practice..
FLINT
发表于 2025-3-22 06:16:19
http://reply.papertrans.cn/67/6659/665852/665852_4.png
adulterant
发表于 2025-3-22 10:54:59
Strategies in ALK Rearranged NSCLC Patientsby the U.S. Food and Drug Administration (FDA) for the treatment of ALK + NSCLC in August 2011 and by the European Medicines Evaluation Agency (EMEA) in July 2012. In this chapter the evidence base for crizotinib is summarized and ongoing strategies to overcome resistance to crizotinib, including other ALK inhibitors in development are discussed.
坚毅
发表于 2025-3-22 16:32:46
New Approaches in Immunotherapyn interesting approach with many antibodies in clinical trials. The most relevant will be discussed here. The cross-links between immunotherapy and anti-angiogenesis as well as combination strategies of immunotherapy are discussed.
不容置疑
发表于 2025-3-22 19:35:08
Minimally Invasive Surgery for Early NSCLC of classical open thoracotomy resections. The minimally invasive options of VATS (video-assisted thoracic surgery), robotic assisted thoracic surgery and uniportal VATS will be reviewed and discussed.
唠叨
发表于 2025-3-23 00:35:11
http://reply.papertrans.cn/67/6659/665852/665852_8.png
Antagonism
发表于 2025-3-23 02:55:25
http://reply.papertrans.cn/67/6659/665852/665852_9.png
animated
发表于 2025-3-23 08:43:51
http://reply.papertrans.cn/67/6659/665852/665852_10.png